drugset / Trial / NCT06887933

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

NCT06887933

Phase 4 Not yet recruiting 67 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn about the safety profile of niraparib in adult female participants for the treatment of advanced or relapsed epithelial ovarian cancer.

Timeline

Start
2025-04-22
Primary completion
2026-03-20
Completion
2026-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule

Indications